{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:33:42Z","timestamp":1790364822499,"version":"4.1.0"},"reference-count":56,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Identification of large B-cell lymphomas that are \u201cextra-aggressive\u201d and may require therapy other than that used for diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS), is of great interest. Large B-cell lymphomas with MYC plus BCL2 and\/or BCL6 rearrangements, so-called \u2018double hit\u2019 (DHL) or \u2018triple hit\u2019 (THL) lymphomas, are one such group of cases often recognized using cytogenetic FISH studies. Whether features such as morphologic classification, BCL2 expression, or type of MYC translocation partner may mitigate the very adverse prognosis of DHL\/THL is controversial. Classification of the DHL\/THL is also controversial, with most either dividing them up between the DLBCL, NOS and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma (BCLU) categories or classifying at least the majority as BCLU. The BCLU category itself has many features that overlap those of DHL\/THL. Currently, there is growing interest in the use of MYC and other immunohistochemistry either to help screen for DHL\/THL or to identify \u201cdouble-expressor\u201d (DE) large B-cell lymphomas, defined in most studies as having \u226540% MYC+ and \u226550%-70% BCL2+ cells. DE large B-cell lymphomas are generally aggressive, although not as aggressive as DHL\/THL, are more common than DHL\/THL, and are more likely to have a nongerminal center phenotype. Whether single MYC rearrangements or MYC expression alone is of clinical importance is controversial. The field of the DHL\/THL and DE large B-cell lymphomas is becoming more complex, with many issues left to resolve; however, great interest remains in identifying these cases while more is learned about them.<\/jats:p>","DOI":"10.1182\/asheducation-2014.1.90","type":"journal-article","created":{"date-parts":[[2014,11,24]],"date-time":"2014-11-24T18:39:03Z","timestamp":1416854343000},"page":"90-99","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":120,"title":["Diagnosis of \u2018double hit\u2019 diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC"],"prefix":"10.1182","volume":"2014","author":[{"given":"Steven H.","family":"Swerdlow","sequence":"first","affiliation":[{"name":"University of Pittsburgh School of Medicine, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111704271536400_B1","first-page":"265","article-title":"B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue","author":"Kluin","year":"2008"},{"issue":"8","key":"2019111704271536400_B2","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood-2010-09-297879","article-title":"Double-hit B-cell lymphomas","volume":"117","author":"Aukema","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2019111704271536400_B3","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/leu.2008.281","article-title":"Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of today's knowledge","volume":"23","author":"Boerma","year":"2009","journal-title":"Leukemia"},{"issue":"9","key":"2019111704271536400_B4","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1136\/jclinpath-2011-200015","article-title":"Fluorescence in situ hybridisation analysis of formalin-fixed paraffin-embedded tissue sections in the diagnostic work-up of non-Burkitt high grade B-cell non-Hodgkin's lymphoma: a single centre's experience","volume":"64","author":"Foot","year":"2011","journal-title":"J Clin Pathol"},{"issue":"12","key":"2019111704271536400_B5","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1182\/blood-2012-06-435842","article-title":"MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma","volume":"121","author":"Horn","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2019111704271536400_B6","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/bjh.12343","article-title":"B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and burkitt lymphoma: study of 39 cases","volume":"162","author":"Perry","year":"2013","journal-title":"Br J Haematol"},{"issue":"7","key":"2019111704271536400_B7","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/modpathol.2013.214","article-title":"Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP","volume":"27","author":"Tzankov","year":"2014","journal-title":"Mod Pathol"},{"issue":"4","key":"2019111704271536400_B8","doi-asserted-by":"crossref","first-page":"726","DOI":"10.3324\/haematol.2013.091827","article-title":"Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma","volume":"99","author":"Aukema","year":"2014","journal-title":"Haematologica"},{"issue":"9","key":"2019111704271536400_B9","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s00277-004-0879-2","article-title":"Coexistence of BCL1\/CCND1 and CMYC aberrations in blastoid mantle cell lymphoma: a rare finding associated with very poor outcome","volume":"83","author":"Michaux","year":"2004","journal-title":"Ann Hematol"},{"issue":"1","key":"2019111704271536400_B10","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/modpathol.2011.147","article-title":"B-cell lymphomas with MYC\/8q24 rearrangements and IGH@BCL2\/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome","volume":"25","author":"Li","year":"2012","journal-title":"Mod Pathol"},{"issue":"2","key":"2019111704271536400_B11","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3960\/jslrt.52.113","article-title":"Double-hit lymphoma with a feature of follicular lymphoma concurrent with clonally related B lymphoblastic leukemia: a preference of transformation for the bone marrow","volume":"52","author":"Kishimoto","year":"2012","journal-title":"J Clin Exp Hematop"},{"issue":"3","key":"2019111704271536400_B12","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/PAS.0b013e3181cd3aeb","article-title":"B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma","volume":"34","author":"Snuderl","year":"2010","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"2019111704271536400_B13","doi-asserted-by":"crossref","first-page":"935","DOI":"10.3324\/haematol.2008.005355","article-title":"Clinicopathological features of lymphoma\/leukemia patients carrying both BCL2 and MYC translocations","volume":"94","author":"Tomita","year":"2009","journal-title":"Haematologica"},{"issue":"11","key":"2019111704271536400_B14","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1182\/blood-2009-03-212191","article-title":"Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood"},{"issue":"5","key":"2019111704271536400_B15","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/j.1365-2559.2012.04301.x","article-title":"High-grade B cell lymphoma, unclassifiable, with blastoid features: an unusual morphological subgroup associated frequently with BCL2 and\/or MYC gene rearrangements and a poor prognosis","volume":"61","author":"Kanagal-Shamanna","year":"2012","journal-title":"Histopathology"},{"issue":"10","key":"2019111704271536400_B16","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.3324\/haematol.2013.086173","article-title":"MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"98","author":"Valera","year":"2013","journal-title":"Haematologica"},{"issue":"20","key":"2019111704271536400_B17","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2012-10-460063","article-title":"MYC\/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"issue":"28","key":"2019111704271536400_B18","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":"Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Johnson","year":"2012","journal-title":"J Clin Oncol"},{"issue":"28","key":"2019111704271536400_B19","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2011.41.4342","article-title":"Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Green","year":"2012","journal-title":"J Clin Oncol"},{"issue":"17","key":"2019111704271536400_B20","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1182\/blood-2009-05-220095","article-title":"MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy","volume":"114","author":"Savage","year":"2009","journal-title":"Blood"},{"key":"2019111704271536400_B21","first-page":"155","article-title":"MYC translocation partner gene is a predictive factor of survival in diffuse large B-cell lymphomas irrespective of single or double hit MYC gene alterations: a LYSA study [abstract]","volume":"31","author":"Copie-Bergman","year":"2013","journal-title":"Hematol Oncol"},{"issue":"20","key":"2019111704271536400_B22","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2009.26.3947","article-title":"Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab","volume":"28","author":"Barrans","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111704271536400_B23","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3324\/haematol.2012.066209","article-title":"Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study","volume":"98","author":"Visco","year":"2013","journal-title":"Haematologica"},{"issue":"6","key":"2019111704271536400_B24","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1002\/cncr.26433","article-title":"Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma","volume":"118","author":"Lin","year":"2012","journal-title":"Cancer"},{"issue":"17","key":"2019111704271536400_B25","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1002\/cncr.27396","article-title":"Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab","volume":"118","author":"Akyurek","year":"2012","journal-title":"Cancer"},{"issue":"14","key":"2019111704271536400_B26","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1200\/JCO.2010.32.8385","article-title":"The gray zone between Burkitt's lymphoma and diffuse large B-cell lymphoma from a genetics perspective","volume":"29","author":"Salaverria","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111704271536400_B27","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/bjh.12901","article-title":"\u2018Double-hit\u2019 cytogenetic status may not be predicted by baseline clinicopathological characteristics and is highly associated with overall survival in B cell lymphoma patients","volume":"166","author":"Landsburg","year":"2014","journal-title":"Br J Haematol"},{"key":"2019111704271536400_B28","article-title":"TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and BCL2 but not MYC and BCL6 translocations","author":"Gebauer","journal-title":"Leuk Lymphoma"},{"key":"2019111704271536400_B29","article-title":"Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era","author":"Vaidya","journal-title":"Ann Oncol"},{"issue":"11","key":"2019111704271536400_B30","first-page":"4771","article-title":"ID3 mutations are recurrent events in double-hit B-cell lymphomas","volume":"33","author":"Gebauer","year":"2013","journal-title":"Anticancer Res"},{"issue":"1","key":"2019111704271536400_B31","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1600-0609.2012.01787.x","article-title":"Double-hit BCL2\/MYC translocations in a consecutive cohort of patients with large B-cell lymphoma - a single centre's experience","volume":"89","author":"Pedersen","year":"2012","journal-title":"Eur J Haematol"},{"issue":"3","key":"2019111704271536400_B32","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/PAS.0b013e31826cebad","article-title":"Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas","volume":"37","author":"Pillai","year":"2013","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"2019111704271536400_B33","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/PAP.0b013e3182a289f2","article-title":"MYC\/BCL2 double-hit high-grade B-cell lymphoma","volume":"20","author":"Li","year":"2013","journal-title":"Adv Anat Pathol"},{"issue":"4","key":"2019111704271536400_B34","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/leu.2008.344","article-title":"Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24\/c-MYC translocations","volume":"23","author":"Niitsu","year":"2009","journal-title":"Leukemia"},{"issue":"11","key":"2019111704271536400_B35","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1002\/cncr.28642","article-title":"Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival","volume":"120","author":"Cohen","year":"2014","journal-title":"Cancer"},{"key":"2019111704271536400_B36","article-title":"Double hit lymphoma: the MD Anderson Cancer Center clinical experience","author":"Oki","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111704271536400_B37","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/ejh.12212","article-title":"MYC translocation partner gene determines survival of patients with large B-cell lymphoma with MYC- or double-hit MYC\/BCL2 translocations","volume":"92","author":"Pedersen","year":"2014","journal-title":"Eur J Haematol"},{"issue":"3","key":"2019111704271536400_B38","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.anndiagpath.2012.11.001","article-title":"Clinicopathological features of aggressive B-cell lymphomas including B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell and Burkitt lymphomas: a study of 44 patients from Argentina","volume":"17","author":"Burgesser","year":"2013","journal-title":"Ann Diagn Pathol"},{"issue":"5","key":"2019111704271536400_B39","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/PPO.0b013e31826aee97","article-title":"The histological and biological spectrum of diffuse large B-cell lymphoma in the world health organization classification","volume":"18","author":"Menon","year":"2012","journal-title":"Cancer J"},{"issue":"4","key":"2019111704271536400_B40","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/PAS.0000000000000147","article-title":"Clinical Significance of MYC Expression and\/or \u201cHigh-grade\u201d Morphology in Non-Burkitt, Diffuse Aggressive B-cell Lymphomas: A SWOG S9704 Correlative Study","volume":"38","author":"Cook","year":"2014","journal-title":"Am J Surg Pathol"},{"issue":"23","key":"2019111704271536400_B41","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa055351","article-title":"A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling","volume":"354","author":"Hummel","year":"2006","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111704271536400_B42","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3324\/haematol.13071","article-title":"Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitt's lymphoma","volume":"93","author":"Salaverria","year":"2008","journal-title":"Haematologica"},{"issue":"12","key":"2019111704271536400_B43","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/ng.2476","article-title":"New pathogenic mechanisms in Burkitt lymphoma","volume":"44","author":"Campo","year":"2012","journal-title":"Nat Genet"},{"issue":"12","key":"2019111704271536400_B44","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/ng.2469","article-title":"Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing","volume":"44","author":"Richter","year":"2012","journal-title":"Nat Genet"},{"issue":"6","key":"2019111704271536400_B45","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/j.1365-2559.2012.04351.x","article-title":"Does the proliferation fraction help identify mature B cell lymphomas with double- and triple-hit translocations?","volume":"61","author":"Mationg-Kalaw","year":"2012","journal-title":"Histopathology"},{"issue":"7","key":"2019111704271536400_B46","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1200\/JCO.2006.09.4490","article-title":"Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications\u2013a study from the Lunenburg Lymphoma Biomarker Consortium","volume":"25","author":"de Jong","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111704271536400_B47","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/bjh.12763","article-title":"MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab","volume":"165","author":"Perry","year":"2014","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111704271536400_B48","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1309\/AJCPL11MAHISIJBQ","article-title":"The unique immunophenotype of double-hit lymphomas","volume":"135","author":"Harrington","year":"2011","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"2019111704271536400_B49","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1309\/AJCP7YLDTJPLCE5F","article-title":"\u201cDouble-Hit\u201d mature B-cell lymphomas show a common immunophenotype by flow cytometry that includes decreased CD20 expression","volume":"134","author":"Wu","year":"2010","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"2019111704271536400_B50","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/cyto.b.21076","article-title":"Flow cytometry is of limited utility in the early identification of \u201cdouble-hit\u201d B-cell lymphomas","volume":"84","author":"Platt","year":"2013","journal-title":"Cytometry B Clin Cytom"},{"issue":"4","key":"2019111704271536400_B51","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/PAS.0b013e318244e2ba","article-title":"High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma","volume":"36","author":"Green","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"2019111704271536400_B52","first-page":"342A","article-title":"Expression profile of MYC protein in lymphoma subtypes","volume":"27","author":"Chisholm","year":"2014","journal-title":"Modern Pathology"},{"key":"2019111704271536400_B53","first-page":"360A","article-title":"MYC protein expression by immunohistochemistry in high grade B-cell lymphomas: concordance rate among hematopathologists","volume":"27","author":"Mahmoud","year":"2014","journal-title":"Modern Pathology"},{"issue":"28","key":"2019111704271536400_B54","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1200\/JCO.2012.44.4729","article-title":"Growing importance of MYC\/BCL2 immunohistochemistry in diffuse large B-cell lymphomas","volume":"30","author":"Pfreundschuh","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111704271536400_B55","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/bjh.12906","article-title":"R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433","volume":"166","author":"Friedberg","year":"2014","journal-title":"Br J Haematol"},{"issue":"21","key":"2019111704271536400_B56","first-page":"3029","article-title":"Concurrent expression of MYC\/BCL2 protein in newly diagnosed DLBCL is not associated with an inferior survival after EPOCH-R therapy [abstract]","volume":"122","author":"Dunleavy","year":"2013","journal-title":"Blood (ASH Annual Meeting Abstracts)"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2014\/1\/90\/1251400\/bep00114000090.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2014\/1\/90\/1251400\/bep00114000090.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T09:27:43Z","timestamp":1573982863000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2014\/1\/90\/20557\/Diagnosis-of-double-hit-diffuse-large-Bcell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,5]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2014.1.90","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,5]]}}}